How to buy CytoDyn shares | CYDY historical share price and analysis

How to buy CytoDyn shares

Own CytoDyn shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

CytoDyn Inc is a biotechnology business with stocks listed in the US. CytoDyn shares (CYDY) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was US$4.28 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in CytoDyn

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CytoDyn. Find the share by name or ticker symbol: CYDY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytoDyn reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$4.28, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CytoDyn, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CytoDyn. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CytoDyn share price

Use our graph to track the performance of CYDY stocks over time.

CytoDyn shares at a glance

Information last updated 2021-03-24.
52-week rangeUS$0.911 - US$10.01
50-day moving average US$4.2794
200-day moving average US$3.8318
Target priceUS$4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-0.188

Compare share trading platforms to buy stock

Data updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy CytoDyn stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CytoDyn price performance over time

Historical closes compared with the last close of $4.28

1 week (2021-04-15) 40.33%
1 month (2021-03-23) 86.09%
3 months (2021-01-22) -14.49%
6 months (2020-10-22) 59.70%
1 year (2020-04-22) 63.58%
2 years (2019-04-22) 866.14%
3 years (2018-04-20) 739.22%
5 years (2016-04-22) 241.04%

CytoDyn financials

Gross profit TTM US$0
Return on assets TTM -77.37%
Return on equity TTM 0%
Profit margin 0%
Book value 0.005
Market capitalisation US$1.4 billion

TTM: trailing 12 months

CytoDyn share dividends

We're not expecting CytoDyn to pay a dividend over the next 12 months.

CytoDyn share price volatility

Over the last 12 months, CytoDyn's shares have ranged in value from as little as US$0.911 up to US$10.01. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.4957. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.

CytoDyn overview

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site